EAF2 protein down-regulation, allelic loss, promoter hypermethylation and possibly homozygous deletion was identified in ∼80% of advanced prostate cancer specimens examined (Gleason ≥7) [6]. This evidence concerns the gene EAF2 and prostate cancer.